Gene expression
CDK2 anchors an immune/ceRNA prognosis model in LUAD
Open access · cc by · source: Europe PMC
Across GEO/TCGA analyses, CDK2 is upregulated with strong LUAD survival association and is embedded in immune, Nomogram, ceRNA, and drug-IC50 networks.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Both markers track immune infiltration, which is what a single-gene score is often measuring.
Single genes recur as prognostic markers across cancers. CDK2 showed highly significant prognostic value in lung adenocarcinoma (P = 5.8e-15) with higher tumour than normal expression and stage and survival links across a pan-cancer analysis; ITGAL discriminated gastric cancer with AUC 0.798 and correlated with CD8 T-cell infiltration (rho = 0.732).
Evidence for the claim as stated.
What counts as validation differs sharply across this literature. The immune aging clocks report internal and external validation on independent data, while the single-gene cancer markers are assessed within the same public repositories used to select them — so the reported AUCs and hazard ratios are not measuring the same property.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
What counts as validation differs sharply across this literature. The immune aging clocks report internal and external validation on independent data, while the single-gene cancer markers are assessed within the same public repositories used to select them — so the reported AUCs and hazard ratios are not measuring the same property.
Inspect source passages
CDK2 anchors an immune/ceRNA prognosis model in LUAD
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
250 overlapping DEGs identified
A total of 250 differentially expressed genes (DEGs) were identified to participate in many cancer-related pathways, such as activation of immune response, cell adhesion, migration, P13K-AKT signaling pathway.
CDK2 LUAD survival P = 5.8e-15
The target molecule CDK2 had prognostic value for the survival of patients in LUAD ( P = 5.8e-15).
Key findings
CDK2 had highly significant LUAD prognostic value (P=5.8e-15) and higher tumor vs normal expression. Pan-cancer analyses showed stage/survival links. Immune modulator genes and a ceRNA network (lncRNAs–miRNAs–CDK2) were constructed; CDK2 associated with IC50 of 89 antitumor drugs.
Methodology
Liu et al. found 250 overlapping DEGs (P<0.01, |logFC|>2), prioritized CDK2, then used UALCAN/Oncomine/TIMER and R survival tools for pan-cancer/LUAD expression and prognosis, built Nomogram and Cox immune forecast models, assembled a ceRNA network, and correlated CDK2 with GDSC drug IC50s.
Limitations
Purely observational public-data associations—no wet-lab causal validation. Nomogram clinical deployment needs prospective calibration.
Related papers in this topic
Same topic cluster — not a recommendation engine.